MagicMed Industries files provisional patent covering psychedelic derivatives
The company expects the filing to be the first in a series of applications that together are designed to protect its portfolio of novel derivatives known as the Psybrary
Sector
Health
1063 stories · page 48 of 54
SUDA Pharmaceuticals to continue focus on cancer, insomnia treatments
SUDA had been progressing towards a proposed material licensing transaction in relation to a cancer therapy technology from a leading US cancer research institute.
Champignon Brands CEO Dr Roger McIntyre authors studies appearing in two leading scientific journals
The articles, looking at safety and efficacy of ketamine as a mental health therapy, were co-authored in conjunction with the Canadian Rapid Treatment Centre of Excellence
Champignon Brands revamps its brand identity to better reflect its scientific focus on psychedelic medicine
The firm is changing its name to Apotheosis Scientific Ltd and spinning out its consumer packaged goods division
Champignon Brands closes C$15 million financing to fund North American ketamine clinical expansion plans
The psychedelic healthcare company sold a total of 17,647,500 units priced at C$0.85
Champignon selects Dalriada Drug Discovery to advance its new chemical entity IP portfolio
Dalriada said it was “excited” to support Champignon’s work in advancing the therapeutic applications of ketamine and psilocybin derivatives
Champignon Brands retains financial marketing service to help raise awareness of North American clinical expansion
Champignon also announced a voluntary share lockup of 17.84 million shares
Champignon Brands adds workplace mental health expert Dr Bill Wilkerson to its board of directors
Wilkerson spearheaded a 14-year-long Canadian initiative to recruit major employers to support employee mental health and previously served as president of Liberty Health
Does ATAI Life Sciences' 'biotech platform' provide the antidote to traditional drug discovery model?
Set up two years ago, it has attracted more than US$100mln in Series A and B funding that has brought in an impressive roster of early investors, including Peter Thiel, the co-founder of both PayPal and Palantir
Champignon Brands sponsors non-profit coalition seeking Psilocybin access for palliative cancer patients
Based in British Columbia, the TheraPsil coalition encompasses healthcare professionals, policy-makers and community leaders aiming to promote access to psychedelic-assisted therapy for those in medical need
Champignon Brands inks deal for California's Wellness Clinic of Orange County as part of North American expansion strategy
The deal represents a key leap forward in the company's strategy to open five new ketamine clinics in the US this year
Champignon Brands to raise $10 million for North American ketamine clinic expansion
The Vancouver-based company plans to open at least five new ketamine clinics in the US by the end of 2020
Champignon Brands appoints psychiatry and pharmacology professor, Roger McIntyre as new CEO
Prior to joining Champignon, McIntyre implemented and developed the Canadian Rapid Treatment Centre of Excellence, the country's first-ever rapid-onset treatment centre for persons with mood disorders
Stabilitech Biopharma working on a breakthrough coronavirus vaccine that can be taken in pill form
“It is as simple as taking an aspirin,” chairman Wayne Channon said of the OraPro-COVID-19 treatment
Champignon Brands appoints MediPharm Labs CEO Pat McCutcheon to board of directors
Prior to founding MediPharm, McCutcheon held senior roles at various large pharmaceutical companies including Jansen Pharmaceuticals, Sanofi and AstraZeneca
Champignon Brands forms North American planning committee to accelerate US expansion
The ketamine clinic operator is in the midst of discussions with revenue-generating clinics in six states as part of its goal to open five US clinics in 2020
Champignon Brands closes deal to acquire ketamine clinic operator AltMed Capital
AltMed recently gained full ownership of the Canadian Rapid Treatment Centre of Excellence
Champignon Brands makes ketamine treatment available at major Canadian pharmacy location
The group will also leverage the pharmacy’s infrastructure to distribute ketamine topical prescriptions to a network of medical, pain and addiction clinics in Canada
Champignon Brands chosen as headline partner for major psychedelics conference in June
The Vancouver-based company will be a main partner for PSYCH: The Psychedelics Symposium, which is scheduled to run virtually between June 22 to 23
Champignon Brands shares begin to trade on the OTCQB Venture Market
The move to the OTCQB opens up a broader base of investors in the US for the Vancouver-based company, which specializes in the formulation of a suite of medicinal mushroom health products